http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Echo-Cancellation Technique With Recursive Data in Nonanechoic Test Sites
Jung-Ick Moon,Soon-Soo Oh,Young-Bae Jung IEEE 2009 IEEE antennas and wireless propagation letters Vol.8 No.-
<P>A simple and effective method of echo cancellation in a nonanechoic chamber with a metal plate is presented in this study. The antenna measurement using standard gain-horn antennas was measured from 3.0 to 3.7 GHz in a fully anechoic chamber with intentionally generated contributions. As a result, when the frequency range is very narrow as one/time delay, the proposed method has better performances than the earlier echo-cancellation techniques such as fast Fourier transformation (FFT) and matrix pencil (MP)-based method.</P>
Byun, Jung-Ick,Lee, Byeong Uk,Kim, Minah,Sunwoo, Jun-Sang,Lim, Jung-Ah,Moon, Jangsup,Lee, Soon-Tae,Jung, Keun-Hwa,Chu, Kon,Kim, Man-Ho,Jeong, Min Hee,Cha, Kwang Su,Choi, Jeong Woo,Kim, Kyung Hwan,Lee, Elsevier 2017 SLEEP MEDICINE Vol.38 No.-
<P><B>Abstract</B></P> <P><B>Objectives</B></P> <P>Idiopathic rapid eye movement sleep behavior disorder (IRBD) patients are prone to cognitive deficits, which include attention, executive, and visuospatial dysfunctions. Even patients with normal cognition may exhibit subclinical electrophysiological dysfunction. This study aimed to evaluate visuospatial attention processing in IRBD patients with normal cognition and to compare their findings with those of age- and sex-matched healthy controls.</P> <P><B>Methods</B></P> <P>We recorded event-related potentials (ERPs) and performance measures during a variant of the Posner task in 14 IRBD patients and 14 control subjects. Behavioral data and the mean P300 amplitude were compared between groups.</P> <P><B>Results</B></P> <P>No group difference was found for reaction time or accuracy, but a significant group effect was observed for the P300 amplitude. IRBD patients had reduced P300 amplitude (μV) than controls in both valid (IRBD: 0.53 ± 1.05 vs Controls: 1.61 ± 0.95; p = 0.008) and invalid (IRBD: 0.74 ± 0.99 vs Controls: 1.73 ± 0.86; p = 0.009) conditions. The P300 amplitude was correlated with Montreal cognitive assessment (MOCA) scores (r = 0.424, p = 0.024).</P> <P><B>Conclusion</B></P> <P>Reduced P300 amplitude during the Posner task provides electrophysiological evidence for subclinical visuospatial attention deficits in cognitively normal IRBD patients. The results of this study imply that cortical dysfunction is already present in patients with IRBD in their early disease stage.</P> <P><B>Highlights</B></P> <P> <UL> <LI> IRBD with normal cognition had reduced P300 amplitude during Posner task. </LI> <LI> Reduced P300 in IRBD was independent of age, sex, depression, and autonomic function. </LI> <LI> The P300 amplitude correlated with MOCA scores. </LI> <LI> Cortical dysfunction may be present in early stage of IRBD. </LI> </UL> </P>
Byun, Jung-Ick,Lee, Soon-Tae,Jung, Keun-Hwa,Sunwoo, Jun-Sang,Moon, Jangsup,Kim, Tae-Joon,Lim, Jung-Ah,Kim, Soyun,Kim, Do-Yong,Han, Su-Hyun,Jang, Hyemin,Suh, Hong Il,Cho, A-Hyun,Kim, Dong Wook,Shin, Ju Elsevier 2016 Journal of neuroimmunology Vol.293 No.-
<P><B>Abstract</B></P> <P>We aimed to evaluate the prevalence of antineuronal antibodies in a nationwide cohort of patients with encephalopathy of unknown etiology. We screened 1699 patients with idiopathic encephalopathy who were referred from 70 hospitals across Korea for autoimmune synaptic and classic paraneoplastic antibodies. Those with cerebellar degeneration, sensory polyneuropathy or other paraneoplastic syndromes without encephalopathy were not included in this study. One-hundred and four patients (6.12%) had antibody-associated autoimmune encephalopathy. Autoimmune synaptic antibodies were identified in 89 patients (5.24%) and classic paraneoplastic antibodies were identified in 16 patients (0.94%). The patients with antibody-associated autoimmune encephalopathy comprised a small but significant portion of the total number of patients with encephalopathy of unknown cause.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Among 1699 patients with encephalopathy of unknown etiology, autoantibody was identified in 6.12%. </LI> <LI> Autoimmune encephalopathy comprised a significant portion of idiopathic cases. </LI> <LI> Anti-NMDA receptor antibody was the most common autoantibody in age under 40. </LI> <LI> Anti-LGI1 antibody was the most common autoantibody in age 40 and over. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort
Lee, Woo-Jin,Lee, Soon-Tae,Byun, Jung-Ick,Sunwoo, Jun-Sang,Kim, Tae-Joon,Lim, Jung-Ah,Moon, Jangsup,Lee, Han Sang,Shin, Yong-Won,Lee, Keon-Joo,Kim, Soyun,Jung, Keun-Hwa,Jung, Ki-Young,Chu, Kon,Lee, Sa Ovid Technologies (Wolters Kluwer) - American Acad 2016 Neurology Vol.86 No.18
<P>Objective: To determine efficacy and safety of rituximab treatment as a second-line immunotherapy treatment for autoimmune limbic encephalitis (ALE) and to determine factors associated with functional improvement and favorable outcome following rituximab treatment. Methods: We recruited 80 patients with ALE who were treated with rituximab as a second-line immunotherapy from the Korea Autoimmune Synaptic and Paraneoplastic Encephalitis Registry and reviewed 81 patients without rituximab as a control. We grouped patients according to the detection or type of antibodies; in addition, we evaluated clinical, laboratory, first-line immunotherapy, and rituximab treatment profiles and defined main outcomes as improvements on the modified Rankin Scale (mRS) score and a favorable mRS score (0-2) at the last follow-up. Results: Functional improvement occurred more frequently in the rituximab group compared to the control group. In the rituximab group, 30 (37.5%) patients had synaptic autoantibodies, 15 (18.8%) in the paraneoplastic autoantibodies, and 35 (43.8%) were antibody-negative. The effect of rituximab was the same regardless of autoantibody status. Additional monthly rituximab therapy and partial response to first-line immunotherapies were associated with mRS score improvements, as well as favorable mRS scores. mRS scores of 4-6 as the worst neurologic status predicted an unfavorable mRS score. There were no reported serious infusion-related or infectious adverse effects of rituximab. Conclusions: Rituximab is effective and safe as a second-line immunotherapy for ALE, regardless of autoantibody status. Additional monthly rituximab therapy might potentiate the efficacy of rituximab. Classification of evidence: This study provides Class IV evidence that rituximab improves mRS scores for patients with autoimmune limbic encephalitis who fail first-line therapy.</P>
Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis
Kim, Tae-Joon,Lee, Soon-Tae,Shin, Jung-Won,Moon, Jangsup,Lim, Jung-Ah,Byun, Jung-Ick,Shin, Yong-Won,Lee, Keon-Joo,Jung, Keun-Hwa,Kim, Young-Soo,Park, Kyung-Il,Chu, Kon,Lee, Sang Kun Elsevier/North Holland 2014 Journal of neuroimmunology Vol.270 No.1
<P>Encephalitis associated with anti-γ-aminobutyric acid-B (GABAB) receptor antibodies has been identified recently. However, only a few cases have been reported to date and its clinical manifestations and prognosis have not been investigated systematically. We identified five cases of GABAB encephalitis in Korea. Here we present the clinical features, treatment responses, and brain positron emission tomography findings of the cases. The patients had a clinical triad of memory changes, seizure, and association with small-cell lung cancer. Early diagnosis and comprehensive immune modulation may provide a good outcome.</P>